Patients sometimes come to our clinic specifically asking for tumour markers. They’ve seen the term in premium health screening package brochures, often presented as comprehensive cancer screening tests — CEA, CA-125, CA-19-9, AFP, PSA, often a combination panel sold as a way to “catch cancer early.” The reasoning seems intuitive: if a blood test can detect cancer, why wouldn’t you want it?
The honest answer is more nuanced. Tumour markers occupy a particular space in medicine — they have real, established uses in specific situations, but those situations are mostly not screening healthy people. When used appropriately (monitoring known cancers, evaluating specific symptoms, following up specific clinical questions), they’re valuable tools. When used as general screening in well-feeling patients, they generate more false alarms than genuine early diagnoses, lead to unnecessary follow-up procedures, and sometimes cause real harm through cascading workups that find nothing significant.
This article walks through what tumour markers actually are, when they genuinely help, when they don’t, and why most professional medical bodies don’t recommend routine tumour marker screening in the general population. The goal is to help you make informed decisions about whether specific tumour markers belong in your testing — not as marketing-driven add-ons, but as clinically appropriate tools when they make sense.
What Tumour Markers Are
Tumour markers are substances — usually proteins — that can be measured in blood and that are sometimes produced by cancer cells (and sometimes by normal cells under certain conditions).
How they work in concept.
Some cancers produce specific substances that enter the bloodstream. Measuring these substances in blood can theoretically detect cancer presence, track tumour size or activity, or identify recurrence after treatment. The concept is appealing — a simple blood test that flags cancer.
How they work in reality.
Most tumour markers also rise in non-cancer conditions — inflammation, infections, benign growths, pregnancy, smoking, certain medications. Many cancers don’t produce detectable elevations in their tumour markers. The relationship between any specific marker and any specific cancer is much messier than the marketing suggests.
False positives are common.
A meaningfully elevated tumour marker in someone who actually has cancer is a useful finding. A mildly elevated tumour marker in someone who’s well is much more likely to be a false alarm than a genuine cancer signal — particularly in low-prevalence screening situations. Statistical principles (positive predictive value depends on disease prevalence in the tested population) mean that screening tests perform much worse in healthy populations than in symptomatic patients.
False negatives also occur.
Cancer present but tumour marker normal. The reassurance of a normal tumour marker test in a healthy person is often false reassurance — many cancers exist without producing detectable marker elevations.
Common Tumour Markers Explained
Brief explanation of markers commonly seen in screening packages:
CEA (carcinoembryonic antigen).
Originally identified in colorectal cancer. Also elevated in various other cancers (lung, breast, pancreatic, others). Frequently elevated in non-cancer conditions — smoking (often elevated in current smokers), inflammatory bowel disease, liver disease, various benign conditions. As a screening test in well-feeling people, CEA generates many more false positives than true positives.
CA-125.
Sometimes marketed as an ovarian cancer screening test. Reality: CA-125 is often normal in early ovarian cancer and elevated in many non-cancer conditions affecting women — endometriosis, fibroids, pelvic inflammatory disease, pregnancy, menstruation, ovarian cysts. As a population screening test for ovarian cancer in average-risk women, CA-125 leads to more harm than benefit — false alarms result in unnecessary surgeries with their own risks. CA-125 is genuinely useful for monitoring known ovarian cancer, evaluating specific pelvic mass symptoms in higher-risk patients, and some other specific clinical uses.
CA-19-9.
Associated with pancreatic cancer and some other gastrointestinal cancers. Also elevated in benign conditions — pancreatitis, biliary obstruction, liver disease, various others. Not recommended for screening in average-risk populations.
AFP (alpha-fetoprotein).
Useful for monitoring liver cancer in patients with established cirrhosis or chronic hepatitis, and for monitoring certain germ cell tumours. Used in screening only in specific high-risk patient groups (cirrhosis, chronic hepatitis B) — not in the general population.
PSA (prostate-specific antigen).
Specific to prostate tissue (benign or cancerous). Used for prostate cancer screening in some contexts but increasingly controversial. PSA elevation often reflects benign prostatic enlargement, prostatitis, or other non-cancer conditions. PSA-based screening identifies many low-grade cancers that may never have caused problems while missing some aggressive cancers. Discussions about PSA screening in men over 50 should be individualised — there’s a reasonable argument for it in some patients, a reasonable argument against in others.
Beta-hCG.
Useful for monitoring certain germ cell tumours, gestational trophoblastic disease, and (of course) for detecting and monitoring pregnancy. Not a general cancer screening test.
Lactate dehydrogenase (LDH).
Elevated in various cancers but also in many benign conditions — exercise, muscle injury, liver disease, infections. Sometimes used in monitoring specific cancers; not a useful general screening test.
Why Screening Healthy People Often Fails
The statistical reality that explains why tumour marker screening doesn’t work well in healthy populations:
Positive predictive value depends on prevalence.
Imagine a test that’s 95% accurate. In a population where 1 in 10 people actually have the condition (high prevalence — symptomatic patients), the test performs well. But in a population where 1 in 1000 people have the condition (low prevalence — healthy people), most positive test results turn out to be false positives. The same test, used in different populations, produces dramatically different real-world performance.
Cascade of follow-up testing.
A positive tumour marker leads to further investigation — imaging studies, sometimes biopsies, sometimes invasive procedures. Each of these has costs, risks, and the potential for further incidental findings that create their own cascades.
Anxiety and false reassurance.
Patients with false positive results experience significant anxiety, sometimes for months while follow-up testing is completed. Patients with false negative results may experience falsely reassuring feelings that delay attention to genuine symptoms.
Lead time bias.
Even when screening finds cancer earlier, this doesn’t always translate to better outcomes. Some cancers have aggressive courses regardless of when they’re detected; finding them earlier just extends the time of knowing about them without changing prognosis.
Overdiagnosis.
Some cancers detected through screening would never have caused problems if left undetected — they grow so slowly or are so unlikely to spread that the patient would have died of something else first. Treating these doesn’t help and can cause harm from treatment side effects.
When Tumour Markers Genuinely Help
Several situations where tumour markers serve real clinical purposes:
Monitoring known cancers.
After cancer diagnosis and treatment, serial tumour marker measurements can detect recurrence earlier than imaging alone. This is one of the most established uses.
Evaluating specific symptoms.
In patients with specific clinical findings suggesting possible cancer (mass, abnormal imaging, specific symptoms), tumour markers add diagnostic information that might guide further workup.
High-risk patient surveillance.
Patients with established conditions that significantly increase cancer risk—cirrhosis (AFP for liver cancer), strong family history of ovarian cancer (CA-125 in some protocols)—sometimes benefit from periodic tumour marker monitoring as part of comprehensive surveillance.
Prognosis and staging.
In newly diagnosed cancers, tumour marker levels can help stage disease, guide treatment intensity, and provide baseline values for monitoring.
Treatment response monitoring.
During cancer treatment, tumour marker trends help assess whether treatment is working.
Specific clinical questions.
Various other specific situations where tumour markers provide useful information to guide management.
Why They Appear in Screening Packages
Despite limited screening utility, tumour markers appear prominently in many premium health screening packages. Several reasons:
Marketing appeal.
The promise of “comprehensive cancer screening” sells. Packages including multiple tumour markers sound more thorough than those without. The marketing value often outweighs the clinical value.
Differentiation between tiers.
Premium packages need features to justify their premium prices. Tumour markers are inexpensive to add but sound impressive — useful for tier differentiation regardless of evidence base.
Patient demand.
Patients often request tumour markers based on family history concerns or general worry. Clinics respond to demand even when professional guidelines don’t recommend the testing.
Variable practice patterns.
Different clinicians and clinics have different views on tumour marker screening. Some are more conservative; some include broader testing. Practice doesn’t always align with strict evidence-based recommendations.
Limited downside per individual test.
Each individual tumour marker test is inexpensive, so adding it to a panel feels low-cost. The cumulative effect of false positives across population-level testing is much greater than any individual test cost suggests.
Specific Cancer Screening That Actually Works
Worth contrasting with cancer screening tests that do have established population-level benefit:
Cervical screening (Pap smear and HPV testing).
One of the genuine success stories of cancer screening. Detects precancerous changes years before cancer develops, allowing treatment that prevents cancer. Recommended for women starting around age 21-25.
Mammography for breast cancer.
Substantial evidence base. Recommended typically starting at age 40-50 depending on guidelines and risk factors, every 1-2 years.
Colorectal cancer screening.
Colonoscopy every 10 years starting at age 45-50, or alternative testing more frequently. Among the most effective cancer screening approaches.
Lung cancer screening for high-risk patients.
Low-dose CT scanning for current or former heavy smokers in specific age ranges. Has established benefits in this high-risk population.
Hepatitis B and C screening.
Not cancer screening per se, but identifies conditions that substantially increase liver cancer risk and that can be treated to reduce risk.
HPV vaccination.
Cancer prevention rather than screening. Prevents the cancers that would otherwise be detected.
These are the cancer screening interventions that have demonstrated population-level benefit in randomised trials. Tumour markers as general screening tools have not.
Practical Recommendations
Some practical guidance for thinking about tumour markers in your own care:
Don’t request tumour markers without specific reason.
If a clinic offers them as part of standard screening, that’s not necessarily wrong, but they’re rarely the most valuable component of the package.
Focus on established cancer screening for your age and sex.
Cervical screening for women, mammography at appropriate age, colonoscopy or alternative starting in 40s-50s, HPV vaccination if appropriate. These have actual evidence.
Consider tumour markers in specific situations.
Family history of specific cancers, established risk factors, specific symptoms, or follow-up of known cancers — these are situations where tumour markers can have appropriate roles. Discuss with your doctor whether they make sense for your specific situation.
Be cautious about results from screening panels.
If a tumour marker comes back mildly elevated as part of a comprehensive screening panel, the most likely explanation is a false positive rather than cancer. Don’t panic — discuss with your doctor what (if any) follow-up is appropriate.
Understand what a normal result means.
Normal tumour markers don’t rule out cancer. They reduce probability somewhat but don’t constitute strong reassurance, particularly for cancers where the marker isn’t very sensitive.
What To Do With Abnormal Tumour Marker Results
If you’ve had a tumour marker come back elevated, a sensible approach:
Don’t panic.
Most elevated tumour markers in screening situations turn out to be false positives or reflect non-cancer conditions.
Repeat the test.
Some elevations are transient and resolve on repeat testing. Confirmation that the elevation is real and sustained is the first step.
Investigate non-cancer causes.
Each tumour marker has many possible non-cancer causes of elevation. Your doctor will consider relevant factors based on which marker is elevated and your clinical context.
Targeted follow-up based on the specific marker.
Different markers point toward different organs/systems for follow-up. Imaging studies, additional blood tests, or specialist consultation may be appropriate depending on findings.
Avoid extensive workups based on isolated mild elevations.
Mild elevations without clinical context rarely warrant extensive imaging or invasive procedures. The harms of unnecessary workups often exceed benefits.
Get Smart Cancer Screening at Dr Prevents
If you’re trying to make sense of cancer screening options — whether you should request tumour markers, what other screening makes sense, how to think about your specific cancer risk — please come in for a consultation. At Dr Prevents, our KL and Selangor clinics offer cancer risk assessment, appropriate evidence-based screening recommendations, and tumour marker testing when genuinely indicated rather than as routine package add-ons.
The right cancer screening for you depends on your age, sex, family history, and specific risk factors — not on whether the marker is bundled in a premium package. Our goal is to deliver screening that genuinely reduces your cancer risk, not to maximise the number of tests run.
📞 Evidence-based cancer screening. Walk in for a consultation today. 🩺